Yarrow Bioscience (YARW) executive compensation, 2025 proxy

David Domzalski, President and Chief Executive Officer, was paid $2M in 2024, down 27% from $2.7M the year before.

Filed
November 12, 2025
Annual meeting
December 12, 2025
Pay year
2024
Named executives
3
CEO total pay
$2M-27% vs prior year
CEO pay in equity
49%$960,750 in awards
CEO Target Bonus
60%Based solely on corporate objectives
NEO Target Bonus
40%75% corporate and 25% individual
Maximum Bonus Opportunity
200%Of target bonus for each NEO

How Domzalski was paid

$2M in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary32%Stock awards27%Option awards22%Non-equity incentive18%All other compensation1%

Named executive officers

ExecutiveTotal
David DomzalskiPresident and Chief Executive Officer$1,973,607
Iain StuartChief Scientific Officer$908,430
Mutya HarschChief Legal Officer, General Counsel and Secretary$891,515

What changed and why

  • $2MDavid Domzalski received $1,973,607 in total compensation for 2024, representing a decrease from the prior year total of $2,716,350.
  • 94.5%Non-equity incentive compensation was paid at 94.5% of target after achieving 92.5% on corporate goals.
  • F.W. Cook served as the independent compensation consulting firm advising the Compensation Committee.
  • Stock options and restricted stock units were granted to align executive interests with long-term stockholder value.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.